Patients with Advanced Malignancies Referred to Phase 1 Trials Want to Discuss Advance Care Planning

Share this content:
(ChemotherapyAdvisor) – Extra efforts are needed to address advance care planning for patients with advanced malignances referred to a phase 1 clinical trials program, research at the MD Anderson Cancer Center suggests. In an article published in the Journal of Clinical Oncology online July 9, a survey found many patients “wanted to avoid” the topic, “because they had come to the phase 1 clinic for cancer therapy,” the authors reported.

Patients with advanced cancer refractory to standard therapy “are the prototypical candidates for phase 1 clinical trials,” the article states. A recent study found this cohort of patients had a median overall survival of 9.0 months after referral to MD Anderson's phase 1 clinical trials program.

Of the 435 individual approached, 215 (49%) returned the completed or partially completed investigator-designed survey; most (69%) were still hopeful about their future.

“Approximately 42% of patients (n=90) reported having a living will, 46% had a medical power of attorney (n=98), and 19% had a do-not-resuscitate (DNR) order (n=40),” the authors wrote. “Having a DNR order in place was significantly more common in individuals who had a living will and/or a medical power of attorney.”

Approximately 20% of participants (n=43) had not discussed advance care planning; of these 59% wanted to discuss this with their physician. Approaches might include interviews with the patient, family members, and health care providers.

“Although we should avoid unnecessary physical suffering, emotional distress, and medical futility, we must respect our patients' personal values, religious beliefs, and willingness to take risks at the end of life, while providing them with an invitation to discuss important issues. It would be beneficial to translate the findings of this study into daily clinical practice by discussing advance care planning early to allow patients to be better prepared for end-of-life care,” they concluded.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs